Navigation Links
Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results
Date:11/9/2011

at could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: the timing of regulatory review and approval is uncertain; regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than we or others do, request additional information, have additional recommendations or change their guidance or requirements before or after approval; the risk that data and other information related to Arena's research and development programs may not meet safety or efficacy requirements or otherwise be sufficient for regulatory approval; Arena's response to the CRL for the lorcaserin NDA or submission of a Marketing Authorization Application for regulatory approval of lorcaserin may not be submitted when anticipated, if at all; unexpected or unfavorable new data; risks related to commercializing new products; Arena's ability to obtain and defend its patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; Arena's ability to obtain adequate funds; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from collaborators; and satisfactory resolution of pending and any future litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.Arena
'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Arena Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
2. Robert Hoffman to Rejoin Arena Pharmaceuticals as Vice President, Finance and Chief Financial Officer
3. Arena Pharmaceuticals Announces Second Quarter 2011 Financial Results
4. Arena and Eisai Announce Results of Re-Adjudication of Rat Mammary Tumors from Lorcaserin Carcinogenicity Study
5. Arena and Eisai Announce Completion of Study Measuring Lorcaserin Concentrations in Human Cerebrospinal Fluid and Related Analyses
6. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, August 9
7. Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension
8. Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals Lorcaserin Achieved Statistically Significant Weight Loss
9. Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments
10. Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
11. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, May 10
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... HOUSTON , July 28, 2014  Houston ... announces that he offers orthodontic treatment with Invisalign. ... area patients can have their teeth straightened without ... same long-term benefits associated with other types of ... enjoy natural looks in addition to better support ...
(Date:7/28/2014)... , July 28, 2014 /PRNewswire/ ... in lifestyle healthcare and subsidiary of ... has acquired Physician Recommended Nutriceuticals (PRN) ® ... and related products for dry eye ... in a transaction worth up to ...
(Date:7/28/2014)... 28, 2014  ResMed (NYSE: RMD ), ... treatment of sleep-disordered breathing and other chronic respiratory conditions, ... against Taiwanese medical device manufacturer APEX Medical ... APEX WiZARD 210 and 220 masks.  The judgment was ... Munich , is appealable, and applies throughout Germany.  ...
Breaking Medicine Technology:Houston Cosmetic Dentist, Dr. Behzad Nazari, Now Offers Orthodontic Treatment with Invisalign 2ALPHAEON Acquires PRN, A Leading Specialty Nutriceutical Company 2ALPHAEON Acquires PRN, A Leading Specialty Nutriceutical Company 3ResMed Receives Permanent Injunction against APEX in Germany, Continues Enforcement of Patents in Europe 2
... YORK, Pa., June 29, 2011 Unilife Corporation ("Unilife" ... UNS) today announced that it has successfully completed the ... key industrial milestone represents the final step in the ... Alan Shortall, CEO of Unilife, said: "The completion of ...
... 29, 2011 Suneva Medical, a privately-held aesthetic ... its core aesthetics injectable business with approval from ... long lasting dermal filler for nasolabial folds or ... a unique, long-lasting treatment, Bellafill provides physicians the ...
Cached Medicine Technology:Unilife Successfully Completes Industrialization of Unifill Syringe 2Unilife Successfully Completes Industrialization of Unifill Syringe 3Unilife Successfully Completes Industrialization of Unifill Syringe 4Suneva Medical Announces Canadian Approval of Bellafill™ 2
(Date:7/28/2014)... revised version of a surgical procedure to treat severe ... than 90 percent of the time in patients treated ... MGH Division of Plastic and Reconstructive Surgery report that ... non-endoscopic procedure all of whom had headaches associated ... relief a year later. The team,s paper has ...
(Date:7/28/2014)... Braintree, Massachusetts (PRWEB) July 28, 2014 ... the Summit Provider Exchange technology solution ... office integration efforts and support collaboration with their ... 242 bed acute-care medical center located in New ... 800,000 seasonal visitors with a variety of inpatient ...
(Date:7/28/2014)... runners are far more likely to die of heat ... new study. The researchers pointed out that ... actually 10 times more likely to develop severe and ... of a young and apparently healthy person due to ... gets a lot more media attention. "This research ...
(Date:7/28/2014)... July 28, 2014 The Oakwood Foundation ... Birkhill, Wang, Songe and Associates, PC that will benefit ... tomorrows to come. , The HBWS group is ... more than $2.5 million in donations. Through their latest ... for the Oakwood Women’s Healthcare Classic for the next ...
(Date:7/28/2014)... Stimulating one of two dopamine-producing regions in the brain ... either isoflurane or propofol. In the August issue ... (MGH) report that rats anesthetized with continuous doses of ... stand up in response to electrical stimulation delivered to ... other major dopamine-releasing area, the substantia nigra, did not ...
Breaking Medicine News(10 mins):Health News:Non-endoscopic migraine surgery provides significant symptom relief 2Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 2Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 3Health News:Heat Stroke a Greater Threat to Endurance Runners Than Heart Problems: Study 2Health News:Stimulation of brain region restores consciousness to animals under general anesthesia 2
... CHESHIRE, Conn., Oct. 11 Alexion,Pharmaceuticals, Inc. (Nasdaq: ... conference call and audio web cast on Thursday, October ... with the release of its,financial results for the third ... results at 6:30 a.m. ET on Thursday,October 25, 2007. ...
... Oct. 11 The following was,written by Andrew ... hormonal birth control. Why can Planned,Parenthood freely market ... an increasing array of restrictions?, Fifty years ... were,lethal. Many people smoked, especially highly visible public ...
... The National Medical,Association (NMA) announced the appointment of ... Director of Health Policy, Mr. Sogie-Thomas,will be responsible ... emerging,healthcare trends and current policy issues. He will ... on state and federal law,regulation, and policy. ...
... Chinese undergraduates showed significant benefit , , , THURSDAY, Oct. ... a day for five days helped to increase energy ... of stress hormones, a small study found. , ... from traditional Chinese medicine, the study participants reported better ...
... World Bank report,says in just two years nearly 20 ... doses of artemisinin-based combination therapy (ACT),are on course to ... Control in Africa., The Progress Report on the ... --- including more than 42 million children under,age five ...
... Receives 2007 Distinctively Blue Award for Hospital ... efforts to,reduce hospital-acquired infections in the mid-Atlantic ... from the BlueCross BlueShield,Association of America. CareFirst ... Award for Innovations for the 100,000 Lives ...
Cached Medicine News:Health News:Sue Birth Control Companies for Your Health, Says American Life League 2Health News:Sue Birth Control Companies for Your Health, Says American Life League 3Health News:Sue Birth Control Companies for Your Health, Says American Life League 4Health News:National Medical Association Selects New Director of Health Policy 2Health News:Meditation a Quick Fix for Stress 2Health News:World Bank Group Report on Malaria in Africa Highlights Progress Towards Goal of Significantly Reducing Malaria Deaths 2Health News:World Bank Group Report on Malaria in Africa Highlights Progress Towards Goal of Significantly Reducing Malaria Deaths 3Health News:National Award Recognizes Delmarva Foundation and CareFirst BlueCross BlueShield Quality Improvement Efforts 2
... cannula with 30 gauge, 4.76 mm tip is ... Cannula is attached to a luer lock high ... inch long), for use with high viscosity substances. ... using visco elastic materials. Flattened, angled tip of ...
20 gauge x 25 mm cannula with 30 degree x 5 mm tip. 30 gauge cannula extends into hub 2 mm from end of hub. 10 per box....
Developed for oculoplastic procedures for corneal and scleral protection. Dimensions enable protector to rest on the sclera and not on the cornea. Easily removed with Bishop-Harmon Forceps. Individua...
The moist air humidifying chamber is designed for the infusion of humidified air during phakic fluid air exchange. Sterile single-use. 10 per box. Most popular size or model....
Medicine Products: